ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario.

ECOG – Eastern Cooperative Oncology Group FISH – fluorescence in situ hybridisation IHC – immunohistochemistry NSCLC – non small cell lung cancer OS – overall survival PFS – progression-free survival;

Journal

Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236

Informations de publication

Date de publication:
2022
Historique:
received: 08 02 2022
entrez: 8 9 2022
pubmed: 9 9 2022
medline: 9 9 2022
Statut: epublish

Résumé

Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, there is limited data on patients with poor performance status. We carried out a retrospective analysis of prospectively collected data of patients with ALK-rearranged NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of 2-4 treated at a single academic cancer centre from January 2013 to November 2018. The outcomes, progression-free survival (PFS) and overall survival (OS) were calculated from the date of diagnosis. SPSS version 20 was used for all statistical calculations. Out of the total 441 ALK-positive patients, 97 (21.9%) had ECOG PS 2-4 (poor PS). The median PFS was 9.3 months (95% CI = 6.6-12.0) as compared to 14.9 months (95% CI = 13.4-16.4) for patients with a PS of 0-1 (HR = 1.38, 95% CI = 1.04-1.84, The ALK-rearranged NSCLC patients with poor PS derived significant benefits with ALK inhibitors. The outcomes were significantly poorer as compared to patients with PS 0-1; the subgroup of patients with PS 2 had better outcomes as compared to patients with PS 3-4.

Sections du résumé

Background UNASSIGNED
Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, there is limited data on patients with poor performance status.
Patients and methods UNASSIGNED
We carried out a retrospective analysis of prospectively collected data of patients with ALK-rearranged NSCLC and Eastern Cooperative Oncology Group (ECOG) PS of 2-4 treated at a single academic cancer centre from January 2013 to November 2018. The outcomes, progression-free survival (PFS) and overall survival (OS) were calculated from the date of diagnosis. SPSS version 20 was used for all statistical calculations.
Results UNASSIGNED
Out of the total 441 ALK-positive patients, 97 (21.9%) had ECOG PS 2-4 (poor PS). The median PFS was 9.3 months (95% CI = 6.6-12.0) as compared to 14.9 months (95% CI = 13.4-16.4) for patients with a PS of 0-1 (HR = 1.38, 95% CI = 1.04-1.84,
Conclusion UNASSIGNED
The ALK-rearranged NSCLC patients with poor PS derived significant benefits with ALK inhibitors. The outcomes were significantly poorer as compared to patients with PS 0-1; the subgroup of patients with PS 2 had better outcomes as compared to patients with PS 3-4.

Identifiants

pubmed: 36072236
doi: 10.3332/ecancer.2022.1407
pii: can-16-1407
pmc: PMC9377804
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1407

Informations de copyright

© the authors; licensee ecancermedicalscience.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
J Thorac Oncol. 2008 Feb;3(2):125-9
pubmed: 18303431
J Thorac Oncol. 2011 Sep;6(9):1474-80
pubmed: 21642865
J Clin Oncol. 2013 Aug 10;31(23):2849-53
pubmed: 23775961
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Lung Cancer. 2014 Feb;83(2):259-64
pubmed: 24300132
N Engl J Med. 2018 Nov 22;379(21):2027-2039
pubmed: 30280657
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
J Thorac Oncol. 2011 Apr;6(4):774-80
pubmed: 21336183
Ann Oncol. 2013 Jan;24(1):59-66
pubmed: 22887466
Lancet Oncol. 2012 Nov;13(11):1161-70
pubmed: 23078958
J Thorac Oncol. 2017 Jul;12(7):1161-1166
pubmed: 28238961
PLoS One. 2016 Sep 16;11(9):e0160752
pubmed: 27637025
Oncotarget. 2019 May 3;10(33):3093-3103
pubmed: 31139322
J Clin Oncol. 2018 Aug 1;36(22):2251-2258
pubmed: 29768118
Lancet. 2017 Mar 4;389(10072):917-929
pubmed: 28126333

Auteurs

Ajaykumar Singh (A)

Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Akhil Kapoor (A)

Medical Oncology, Homi Bhabha Cancer Hospital, Varanasi 221001, Uttar Pradesh, India.

Vanita Noronha (V)

Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Vijay Patil (V)

Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Nandini Menon (N)

Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Abhishek Mahajan (A)

Radiology Department, Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Amit Janu (A)

Radiology Department, Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Nilendru Purandare (N)

Nuclear Medicine, Medical Oncology Tata Memorial Centre, Mumbai 400012, India.

Rajiv Kaushal (R)

Pathology, Medical Oncology Tata Memorial Centre, Mumbai 400012, India.

Kumar Prabhash (K)

Medical Oncology, Tata Memorial Centre, Mumbai 400012, India.

Classifications MeSH